Positive Allosteric Modulator
Merck Serono and Domain to co-develop Parkinson’s drugs
January 18, 2011Research and Development Domain Therapeutics, Merck KGaA, Merck Serono, PAM, Parkinson's disease, Parkinson’s disease, Positive Allosteric Modulator, mGluR4, metabotropic glutamate receptor 4
Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
